FB101 Intervention in Asymptomatic Healthy Volunteers Who Have Undergone Vaginal Microbiome Screening - a Randomised, Double-blind, Placebo-controlled Study
Latest Information Update: 03 Jul 2023
At a glance
- Drugs FB 101 (Primary)
- Indications Dysbiosis; Female infertility
- Focus Therapeutic Use
- Acronyms DYSCOVER-1
- Sponsors Freya Biosciences
- 27 Jun 2023 According to Freya Biosciences Media Release, initial results will be shared by Johan van Hylckama Vlieg, Chief Scientific Officer of Freya Biosciences at the Microbiome Movement Summit in Boston later this month.
- 27 Jun 2023 Results published in the Freya Biosciences Media Release
- 01 May 2023 Status changed from recruiting to completed.